WO2008043911A3 - Complexes chelates dendritiques, leurs procedes de fabrication et compositions pharmaceutiques les contenant - Google Patents

Complexes chelates dendritiques, leurs procedes de fabrication et compositions pharmaceutiques les contenant Download PDF

Info

Publication number
WO2008043911A3
WO2008043911A3 PCT/FR2007/001645 FR2007001645W WO2008043911A3 WO 2008043911 A3 WO2008043911 A3 WO 2008043911A3 FR 2007001645 W FR2007001645 W FR 2007001645W WO 2008043911 A3 WO2008043911 A3 WO 2008043911A3
Authority
WO
WIPO (PCT)
Prior art keywords
same
dendritic
pharmaceutical compositions
methods
compositions containing
Prior art date
Application number
PCT/FR2007/001645
Other languages
English (en)
Other versions
WO2008043911A2 (fr
Inventor
Delphine Felder-Flesch
Jérôme STEIBEL
Annabelle Bertin
Original Assignee
Centre National De La Recherche Scientifique
Universite Louis Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National De La Recherche Scientifique, Universite Louis Pasteur filed Critical Centre National De La Recherche Scientifique
Priority to EP07858413A priority Critical patent/EP2079682A2/fr
Priority to JP2009531870A priority patent/JP5149905B2/ja
Priority to US12/444,817 priority patent/US8404216B2/en
Publication of WO2008043911A2 publication Critical patent/WO2008043911A2/fr
Publication of WO2008043911A3 publication Critical patent/WO2008043911A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/124—Macromolecular compounds dendrimers, dendrons, hyperbranched compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/16—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of hydrocarbon radicals substituted by amino or carboxyl groups, e.g. ethylenediamine-tetra-acetic acid, iminodiacetic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/76—Metal complexes of amino carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6524—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having four or more nitrogen atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
    • C08G83/002—Dendritic macromolecules

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des complexes chélatés dendritiques, leurs procédés de fabrication et les compositions pharmaceutiques les contenant. Les complexes chélatés dendritiques selon l'invention ont la formule I suivante : [[MC]-En-[D]m-X1p1X2p2X3p3 X4p4]z - z B+ (I), dans laquelle M est un marqueur magnétique ou scintigraphique, C est un agent chélatant du marqueur magnétique M, E est un espaceur, n = 0 ou 1, D est un composé apte à former une structure dendritique, m est un entier valant 1 ou 2 ou 4, X1 est un groupement augmentant la lipophilie du complexe, p1 est un entier valant de 0 à 12 inclus, X2 est un groupement augmentant la spécificité du complexe pour un organe particulier, p2 est un entier valant 0, 1, 2, ou 4 inclus, X3 est un groupement ayant une activité thérapeutique, p3 est un entier valant 0, 1, 2, ou 4 inclus, X4 est un groupement CH3, p4 est un entier valant de 0 à 12 inclus, B est un contre ion, z est un entier valant 0, 1, 2, 3 ou 4. L'invention trouve application dans le domaine pharmaceutique, plus particulièrement dans le domaine de l'imagerie médicale.
PCT/FR2007/001645 2006-10-09 2007-10-09 Complexes chelates dendritiques, leurs procedes de fabrication et compositions pharmaceutiques les contenant WO2008043911A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP07858413A EP2079682A2 (fr) 2006-10-09 2007-10-09 Complexes chelates dendritiques, leurs procedes de fabrication et compositions pharmaceutiques les contenant
JP2009531870A JP5149905B2 (ja) 2006-10-09 2007-10-09 樹状キレート化合物、該化合物の製造方法及び該化合物を含有する医薬組成物
US12/444,817 US8404216B2 (en) 2006-10-09 2007-10-09 Dendritic chelated compounds, methods for making the same and pharmaceutical compositions containing the same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0608836A FR2906806B1 (fr) 2006-10-09 2006-10-09 Complexes chelates dendritiques, leurs procedes de fabrication et compositions pharmaceutiques les contenant
FR0608836 2006-10-09

Publications (2)

Publication Number Publication Date
WO2008043911A2 WO2008043911A2 (fr) 2008-04-17
WO2008043911A3 true WO2008043911A3 (fr) 2014-12-18

Family

ID=38099018

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2007/001645 WO2008043911A2 (fr) 2006-10-09 2007-10-09 Complexes chelates dendritiques, leurs procedes de fabrication et compositions pharmaceutiques les contenant

Country Status (5)

Country Link
US (1) US8404216B2 (fr)
EP (1) EP2079682A2 (fr)
JP (1) JP5149905B2 (fr)
FR (1) FR2906806B1 (fr)
WO (1) WO2008043911A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8227628B2 (en) 2008-07-09 2012-07-24 Northwestern University Method of synthesizing acetonide-protected catechol-containing compounds and intermediates produced therein
KR101171483B1 (ko) * 2010-02-16 2012-08-07 대림산업 주식회사 글리콜 모노-터셔리-부틸에테르 화합물의 제조 방법 및 이에 의해 제조된 글리콜 모노-터셔리-부틸에테르 화합물
FR2959227B1 (fr) * 2010-04-23 2012-06-22 Centre Nat Rech Scient Nano-objets magneto-optiques pour la detection des cancers
EP2428503B1 (fr) * 2010-09-10 2014-12-10 Justus-Liebig-Universität Gießen Synthèse de dérivés de catéchol tripodaux flexibles pour la fonctionnalisation de surfaces
US9623127B2 (en) * 2011-11-18 2017-04-18 Centre National De La Recherche Scientifique Multimodal contrast and radiopharmaceutical agent for an imaging and a targeted therapy guided by imaging
FR2995902B1 (fr) * 2012-09-26 2014-11-21 Centre Nat Rech Scient Nouveaux composes comportant des groupements dendrimeriques iodes ou fluores, leurs procedes de preparation et leurs utilisations
FR3005954A1 (fr) * 2013-05-23 2014-11-28 Univ Strasbourg Composes dendritiques comprenant un agent chelatant, fluorochrome ou agent de reconnaissance, compositions les comprenant et leurs utilisations
WO2014184503A1 (fr) * 2013-05-16 2014-11-20 Universite De Strasbourg Composés dendritiques comprenant un agent chélatant, fluorochrome ou agent de reconnaissance, compositions les comprenant et leurs utilisations
CA2954555A1 (fr) * 2014-07-11 2016-01-14 The University Of Akron Composition et procedes de fixation de peptides biologiquement actifs sur des surfaces d'oxydes metalliques
KR101625656B1 (ko) * 2015-10-16 2016-05-30 최경석 자기공명영상용 조영제의 제조방법
GB201613166D0 (en) * 2016-07-29 2016-09-14 Vectura Ltd Polymer
CN106883252B (zh) * 2017-03-21 2021-12-17 江汉大学 一种具有高磁熵变的环形钆配合物及其制备方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2867473A1 (fr) * 2004-03-12 2005-09-16 Guerbet Sa Compose de porphyrines et utilisation a haut champ en irm
US6982324B1 (en) * 2001-11-13 2006-01-03 University Of Utah Research Foundation Degradable macromolecular magnetic resonance imaging contrast agents and methods thereof
WO2006033766A2 (fr) * 2004-08-25 2006-03-30 The Regents Of The University Of Michigan Compositions a base de dendrimeres et procedes d'utilisation de celles-ci
US20060165601A1 (en) * 2004-12-30 2006-07-27 Industrial Technology Research Institute Dendritic compound and use thereof
WO2006088958A2 (fr) * 2005-02-15 2006-08-24 Dendritic Nanotechnologies, Inc. Polymeres dendritiques (chelate ou ligand) encapsules
FR2883562A1 (fr) * 2005-03-24 2006-09-29 Guerbet Sa Chelates lipophiles et leur utilisation en imagerie

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5527524A (en) * 1986-08-18 1996-06-18 The Dow Chemical Company Dense star polymer conjugates
US5756726A (en) * 1995-06-02 1998-05-26 Pharmacyclics, Inc. Methods of producing singlet oxygen using compounds having improved functionalization
US20060018835A1 (en) * 2004-04-02 2006-01-26 General Electric Company Nanoparticles with inorganic core and methods of using them
CN101218204A (zh) * 2005-07-08 2008-07-09 詹森药业有限公司 改性的聚（丙烯亚胺）树枝状聚合物及其作为用于阴离子生物活性因子的转染剂的用途

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982324B1 (en) * 2001-11-13 2006-01-03 University Of Utah Research Foundation Degradable macromolecular magnetic resonance imaging contrast agents and methods thereof
FR2867473A1 (fr) * 2004-03-12 2005-09-16 Guerbet Sa Compose de porphyrines et utilisation a haut champ en irm
WO2006033766A2 (fr) * 2004-08-25 2006-03-30 The Regents Of The University Of Michigan Compositions a base de dendrimeres et procedes d'utilisation de celles-ci
US20060165601A1 (en) * 2004-12-30 2006-07-27 Industrial Technology Research Institute Dendritic compound and use thereof
WO2006088958A2 (fr) * 2005-02-15 2006-08-24 Dendritic Nanotechnologies, Inc. Polymeres dendritiques (chelate ou ligand) encapsules
FR2883562A1 (fr) * 2005-03-24 2006-09-29 Guerbet Sa Chelates lipophiles et leur utilisation en imagerie

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
D. IMBERT ET AL: "Synthesis and iron(III) complexing ability of CacCAM, a new analog of enterobactin possessing a free carboxylic anchor arm. Comparative studies with TRENCAM", NEW J. CHEM., vol. 24, 2000, pages 281 - 288, XP002437468 *
THOMAS F ET AL: "Partition Coefficients (Free Ligands and their Iron(III) Complexes) and Lipophilic Behavior of New Abiotic Chelators. Correlation to Biological Activity", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 9, no. 20, 18 October 1999 (1999-10-18), pages 3035 - 3040, XP004180533, ISSN: 0960-894X *
WIENER E C ET AL: "DENDRIMER-BASED METAL CHELATES: A NEW CLASS OF MAGNETIC RESONANCE IMAGING CONTRAST AGENTS", MAGNETIC RESONANCE IN MEDICINE, ACADEMIC PRESS, DULUTH, MN, US, vol. 31, no. 1, January 1994 (1994-01-01), pages 1 - 8, XP000423671, ISSN: 0740-3194 *

Also Published As

Publication number Publication date
FR2906806B1 (fr) 2012-12-14
FR2906806A1 (fr) 2008-04-11
EP2079682A2 (fr) 2009-07-22
JP2010507571A (ja) 2010-03-11
WO2008043911A2 (fr) 2008-04-17
US20100104512A1 (en) 2010-04-29
US8404216B2 (en) 2013-03-26
JP5149905B2 (ja) 2013-02-20

Similar Documents

Publication Publication Date Title
WO2008043911A3 (fr) Complexes chelates dendritiques, leurs procedes de fabrication et compositions pharmaceutiques les contenant
JP6445648B2 (ja) キレート化複合ミセルを有する薬物キャリア及びその応用
GEP20125599B (en) Proteasome inhibitors
WO2005063745A3 (fr) Nouveaux composes de spiroindoline ou de spiroisoquinoline, methodes d'utilisation et compositions associees
EP3116872A1 (fr) Polythérapie avec des inhibiteurs de glutaminase
TWI316942B (en) Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
IL198115A (en) The heteroaryl compounds, their vehicles, and their use in drug preparation
TW200724136A (en) Pharmaceutical compositions comprising PPAR modulator
MY153046A (en) Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof
TW201010733A (en) New L-glutamic acid and L-glutamine derivative (III), use thereof and method for obtaining them
MX2010003868A (es) Cis-imidazolinas quirales.
RS84904A (en) Combined use of antitumor indolopyrrolocarbazole derivative and other antitumor agent
MX2007004740A (es) Derivados de 2-amido-4-feniltiazol, su preparacion y su aplicacion en terapeutica.
TW200714598A (en) Urea derivatives, methods for their manufacture, and uses therefor
HK1099200A1 (en) Anti-inflammatory agents
JP2008542386A5 (fr)
WO2008132552A3 (fr) Nouveaux composés lipidiques
WO2009019708A3 (fr) Compositions pharmaceutiques et procédés pour le traitement du cancer
SG145570A1 (en) 4-æ7-halo-2-quino(xa-)linyloxy!phenoxy-propionic acid derivatives as antineoplastic agents
Wang et al. Synthesis and characterization of new antibacterial fluoride-releasing monomer and dental composite
RU2003134629A (ru) Соединения цефема
KR101678865B1 (ko) 암의 치료에 사용하기 위한 화합물들
TW200740428A (en) Substituted propanamide derivatives and pharmaceutical compositions thereof
MX2009006003A (es) Composicion que contiene derivados de aurona con fines de diagnostico.
UA93190C2 (ru) Соединения нафталина, способ их получения и фармацевтическая композиция, которая их содержит

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07858413

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2009531870

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2007858413

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007858413

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12444817

Country of ref document: US